Recombinant Human Activated Protein C Administered Twice to The Same Patient with Shock Caused by the Acute Pancreatitis and With Septic Shock As Iatrogenic Complication

• Authors: Zbigniew Rybicki , Andrzej Truszczyński , Marcin Skibiński
• Languages of publication: EN

Abstracts

EN

We present a case of a patient suffering from severe acute pancreatitis who underwent double treatment with recombinant human activated protein C. The first administration occurred while the patient was in shock secondary to severe acute pancreatitis (not complicated by pancreatic necrosis bacterial contamination). The second administration occurred while the patient was in septic shock secondary to an iatrogenic complication, which developed in convalescent period.

Keywords

EN

pancreatitis; shock; recombinant human activated protein C

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2007
• Volume: 79
• Issue: 1
• Pages: 47-51

Dates

published

1 - 1 - 2007

online

24 - 9 - 2007

Contributors

author

Zbigniew Rybicki

• Department of Anesthesiology and Intensive Therapy, Military Institute of Health Services, Warsaw

author

Andrzej Truszczyński

• Department of Anesthesiology and Intensive Therapy, Military Institute of Health Services, Warsaw

author

Marcin Skibiński

• Department of Anesthesiology and Intensive Therapy, Military Institute of Health Services, Warsaw

References

• Wyncoll D: The treatment of severe acute necrotising pancreatitis: an evidence - based of the literature. Intensive Care Med 1999; 25: 146-56.
• Bernard GR, Vincent IL, Lattere PF et al.: Efficacy and safety of recombinant human Activated Protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 1494-1512.
• Tooull M, Brooke-Smith M, Bassi C et al.: Guidelines for the management of acute pancreatitis. J Gastroenterol and Hepatol 2002; 17: 15-39.[Crossref]
• Powell IJ, Faeron KCH, Sirivardena AK: Current concepts of the pathophisiology and treatment of severe acute pancreatitis. J Intensive Care 2000; 10: 51-59.
• Berger HG, Bittner R, Block S et al.: Bacterial contamination of pancreatic necrosis. A prospeTKive study. Gastroenterology 1986; 91: 433-38.
• Denham W, Norman J: The potential role of therapeutic cytokine manipulation in acute pancreatitis. Surg Clin Nord Am 1999; 79: 767-81.
• Renzulli P, Jakob SM, Tauber M et al.: Severe acute pancreatitis: case oriented discussion of interdisciplinary management. Pancreatology 2005; 5: 145-56.
• Dib M, Zhao X, Wang X et al.: Acute phase response in acute pancreatitis: a comparison with abdominal sepsis. Scand J Gastroenterol 2003; 38(10): 1072-77.[PubMed]
• Bernard GR, Vincent JL, Laterre PF et al.: Efficacy and safety of recombinant human activated protein C for devere sepsis. N Engl J Med 2001; 344: 699-709.
• Yamanel L, Mas MR, Comert B et al.: The effect of activated protein C on experimental acute necroziting pancreatitis. Crit Care 2005; 9(3): R184-90.[Crossref]
• Machała W, Wachowicz N, Komorowska A et al.: The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Med Sci Monit 2004; 10(7): CS 32-36.

Identifiers

DOI

10.2478/v10035-007-0008-8